Research programme: protein-based companion diagnostics for autoimmune disorders - Protagen/QIAGEN
Latest Information Update: 21 Dec 2014
At a glance
- Originator Protagen AG; QIAGEN
- Class Diagnostic agents; Proteins
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 18 Nov 2014 Early research in Autoimmune disorders (Diagnosis) in Germany (unspecified route)